珂立苏治疗新生儿呼吸窘迫综合症研究

目的：探讨肺表面活性物质（Ps）珂立苏（Calsurf）对新生儿呼吸窘迫综合征（NRDS）的治疗效果。方法：将符合标准的52例患儿在给予相同综合治疗的基础上分为两组：治疗组（珂立苏）及对照组（不用珂立苏），比较两组NRDS临床呼吸机通气参数、机械通气时间、血气变化。结果：治疗组呼吸机通气参数、机械通气时间明显低于对照组，均有显著性改善（P〈0．05）；用药后，抽血气分析监测pH、氧分压（PaO2）及二氧化碳分压（PaCO2），其较用药前均显著性改善（P〈0．05）。肺炎、肺出血、颅内出血并发症没有明显增加。结论：珂立苏能够显著提高NRDS疗效，使用安全。

Therapeutic effect of Calsurf on neonatal respiratory distress syndrome

Objective To explore the clinical therapeutic effect of Calsurf for neonatal respiratory distress syndrome （NRDS）. Methods Fifty--two neonates with NRDS were divided into two groups. Twenty--six received Calsurf and the other twenty- six didn＇ t receive Calsurf. The breathing machine ventilating parameter, the duration of mechanical ventilation and the pH,PaO2 ,PaCO2 of neonates after treatment in the two groups were compared. Results In the therapeutic group ,the breathing machine ventilating parameter and the duration of mechanical ventilation were lower significantly than those in the control group. The pH,PaO2,PaCO2 of neonates in the treatment group were improved significantly after treatment （P〈0.05）. There were significant differences between the two groups （P〈0. 05）. There was no complications such as pneumonia, pneumorrhagia and intracranial hemorrhage. Conclusion The treatment with Calsurf for NRDS can signifiacantly improve the therapeutic effect. It is safe to use Calsurf for neonates.